Curcumin serves as a human Kv1.3 blocker to inhibit effector memory T lymphocyte activities

Phytotherapy Research

Volumn 27, Issue 9, 2013, Pages 1321-1327

  Lian, Yi Tian ^a   Yang, Xiao Fang ^a   Wang, Zhao Hui ^a   Yang, Yong ^a   Yang, Ying ^a   Shu, Yan Wen ^a   Cheng, Long Xian ^a   Liu, Kun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

autoimmune disease; curcumin; human; Kv1.3 channels; TEM cells

Indexed keywords

CURCUMIN; GAMMA INTERFERON; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.3;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS;

CURCUMA LONGA;

AUTOIMMUNE DISEASE; CURCUMIN; HUMAN; KV1.3 CHANNELS; TEM CELLS;

ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HEK293 CELLS; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; KV1.3 POTASSIUM CHANNEL; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

EID: 84883739523     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4863     Document Type: Article

References (37)

1. Aggarwal BB, Sundaram C, Malani N, Ichikawa H,. 2007. Curcumin: the Indian solid gold. Adv Exp Med Biol 595: 1-75.
2. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB,. 2007. Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807-818.
3. Beeton C, Wulff H, Standifer NE, et al,. 2006. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A 103: 17414-17419.
4. Bernard K, Wang W, Narlawar R, Schmidt B, Kirk KL,. 2009. Curcumin cross-links cystic fibrosis transmembrane conductance regulator (CFTR) polypeptides and potentiates CFTR channel activity by distinct mechanisms. J Biol Chem 284: 30754-30765.
5. Bharti AC, Donato N, Aggarwal BB,. 2003. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171: 3863-3871.
6. Bright JJ,. 2007. Curcumin and autoimmune disease. Adv Exp Med Biol 595: 425-451.
7. Cahalan MD, Wulff H, Chandy KG,. 2001. Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol 21: 235-252.
8. Chandy KG, DeCoursey TE, Cahalan MD, McLaughlin C, Gupta S,. 1984. Voltage-gated potassium channels are required for human T lymphocyte activation. J Exp Med 160: 369-385.
9. + channels as targets for specific immunomodulation. Trends Pharmacol Sci 25: 280-289.
10. Cheng AL, Hsu CH, Lin JK, et al,. 2001. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895-2900.
11. + channels and stimulates cortisol secretion from adrenocortical cells. Biochem Biophys Res Commun 370: 623-628.
12. Epstein J, Sanderson IR, Macdonald TT,. 2010. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 103: 1545-1557.
13. Funk JL, Oyarzo JN, Frye JB, et al,. 2006. Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. J Nat Prod 69: 351-355.
14. Goel A, Aggarwal BB,. 2010. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62: 919-930.
15. Hamaguchi T, Ono K, Yamada M,. 2010. REVIEW: Curcumin and Alzheimer's disease. CNS Neurosci Ther 16: 285-297.
16. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV,. 2008. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65: 1631-1652.
17. + T lymphocytes. J Immunol 179: 4563-4570.
18. Khanna S, Park HA, Sen CK, et al,. 2009. Neuroprotective and anti-inflammatory properties of a novel demethylated curcuminoid. Antioxid Redox Signal 11: 449-468.
19. Kim GY, Kim KH, Lee SH, et al,. 2005. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol 174: 8116-8124.
20. Lao CD, Ruffin MT, Normolle D, et al,. 2006. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 17: 6-10.
21. Liacini A, Sylvester J, Li WQ, Zafarullah M,. 2002. Inhibition of interleukin-1- stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 21: 251-262.
22. Liacini A, Sylvester J, Li WQ, et al,. 2003. Induction of matrix metalloproteinase- 13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res 288: 208-217.
23. Liu H, Danthi SJ, Enyeart JJ,. 2006. Curcumin potently blocks Kv1.4 potassium channels. Biochem Biophys Res Commun 344: 1161-1165.
24. Matsushita Y, Ohya S, Itoda H, et al,. 2008. Molecular mechanisms for Kv1.3 potassium channel current inhibition by CD3/CD28 stimulation in Jurkat T cells. Biochem Biophys Res Commun 374: 152-157.
25. Natarajan C, Bright JJ,. 2002. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 168: 6506-6513.
26. Pari L, Tewas D, Eckel J,. 2008. Role of curcumin in health and disease. Arch Physiol Biochem 114: 127-149.
27. Rangaraju S, Chi V, Pennington MW, Chandy KG,. 2009. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis. Expert Opin Ther Targets 13: 909-924.
28. Ruffin MT,. 2003. Dose escalation of curcumin in healthy adults. Cancer Epidemiol Biomarkers Prev 12: 1324S-1324S.
29. Shakibaei M, Schulze-Tanzil G, John T, Mobasheri A,. 2005. Curcumin protects human chondrocytes from IL-l1beta-induced inhibition of collagen type II and beta1-integrin expression and activation of caspase-3: An immunomorphological study. Ann Anat 187: 487-497.
30. Sharma RA, Steward WP, Gescher AJ,. 2007. Pharmacokinetics and pharmacodyna- mics of curcumin. Adv Exp Med Biol 595: 453-470.
31. + channels by curcumin in Jurkat-T cells. J Pharmacol Sci 115: 144-154.
32. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS,. 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64: 353-356.
33. Srivastava RM, Singh S, Dubey SK, Misra K, Khar A,. 2011. Immunomodulatory and therapeutic activity of curcumin. Int Immunopharmacol 11: 331-341.
34. Vareed SK, Kakarala M, Ruffin MT, et al,. 2008. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17: 1411-1417.
35. Varga Z, Hajdu P, Panyi G,. 2010. Ion channels in T lymphocytes: an update on facts, mechanisms and therapeutic targeting in autoimmune diseases. Immunol Lett 130: 19-25.
36. + channel in effector memory T cells as new target for MS. J Clin Invest 111: 1703-1713.
37. + channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol 173: 776-786